- Home
- NMI vs ELDN Comparison
NMI vs ELDN Comparison
Compare NMI & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMI | ELDN |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.0M | 123.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NMI | ELDN |
|---|---|---|
| Price | $10.02 | $1.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 28.4K | ★ 933.4K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.30 | $1.35 |
| 52 Week High | $10.05 | $4.97 |
Technical Indicators
Market Signals| Indicator | NMI | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 59.03 | 46.58 |
| Support Level | $9.90 | $1.44 |
| Resistance Level | $10.23 | $1.67 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 45.45 | 80.77 |
Price Performance
Historical ComparisonAbout NMI Nuveen Municipal Income Fund Inc.
Nuveen Municipal Income Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.